Phospho-TEK (Y1102) Antibody

Basic Research Questions

• What is the biological significance of TEK/TIE2 phosphorylation at the Y1102 position?

  Phosphorylation at Y1102 is a critical event in TIE2 receptor signaling. This specific phosphorylation site serves as a docking site for adaptor proteins including SHC1, GRB2, and GRB7 . When angiopoietin-1 (ANGPT1) binds to TIE2, it triggers receptor dimerization and autophosphorylation at specific tyrosine residues, including Y1102 . This site is particularly important for downstream signal transduction pathways that regulate angiogenesis, endothelial cell survival, proliferation, migration, and vascular stability . In quiescent vessels, phosphorylation leads to activation of phosphatidylinositol 3-kinase and AKT1 signaling cascades, while in migrating endothelial cells, it contributes to focal adhesion complex formation and activation of MAPK pathways .

• How do phospho-specific TEK antibodies differ from regular TIE2 antibodies?

  Phospho-specific TEK antibodies like anti-phospho-Y1102 recognize TIE2 only when phosphorylated at the particular tyrosine residue, whereas regular TIE2 antibodies detect the protein regardless of its phosphorylation status . The specificity is achieved through sophisticated manufacturing methods involving:

  • Antigen design utilizing synthetic phosphopeptides corresponding to the region around Y1102

  • Multiple immunization strategies

  • Extensive affinity purification using both positive and negative adsorption methodologies

  These antibodies are validated through techniques including phosphopeptide/non-phosphopeptide competition experiments and analysis of site-directed mutants, ensuring they only detect the phosphorylated form of the protein .

• What sample types can be analyzed using Phospho-TEK (Y1102) antibodies?

  Phospho-TEK (Y1102) antibodies have been validated for:

  • Cell lines: Human umbilical vein endothelial cells (HUVECs) , NIH-3T3 cells transfected with TIE2

  • Tissues: Paraffin-embedded human brain tissue , human placenta sections

  • Primary cells: Endothelial cells from various vascular beds

  These antibodies are particularly useful for studying TIE2 phosphorylation in contexts where angiopoietin signaling is relevant, such as developing vasculature, tumor angiogenesis, and vascular inflammation models .

Advanced Research Questions

• How can I distinguish between specific and non-specific binding when using Phospho-TEK (Y1102) antibodies?

  To distinguish between specific and non-specific binding, researchers can employ a multi-dimensional analysis approach similar to what's described for phospho-tau antibodies :

  1. Dual-population cell system: Create two populations of cells - one expressing wild-type TIE2 and another expressing a Y1102A mutant (where tyrosine is replaced with alanine)

  2. Differential tagging: Label these populations with distinct fluorescent proteins (e.g., EGFP for wild-type and iRFP for the mutant)

  3. Mixed population analysis: Mix the populations and treat with angiopoietin-1 to induce phosphorylation

  4. Flow cytometry analysis: Any antibody signal in the mutant (iRFP+) population represents non-specific binding

  This approach allows quantification of specificity within a single sample by calculating the ratio of specific to non-specific binding . Lambda phosphatase treatment can also be used to dephosphorylate samples as a negative control .

• How do different angiopoietins affect TIE2 Y1102 phosphorylation status?

  TIE2 receptor signaling is modulated differently by various angiopoietins:

  • ANGPT1: Induces strong Y1102 phosphorylation, promoting vascular stability and anti-inflammatory effects . Western blot analysis shows robust phosphorylation of TIE2 at Y1102 in NIH-3T3 cells treated with 600 ng/mL recombinant ANGPT1 for 5 minutes .

  • ANGPT2: Has lower affinity for TIE2 and can promote autophosphorylation in the absence of ANGPT1, but generally inhibits ANGPT1-mediated phosphorylation by competing for the same binding site .

  • Hypoxic conditions: ANGPT1-induced phosphorylation is impaired during hypoxia due to increased expression of ANGPT2 , demonstrating how microenvironmental factors influence Y1102 phosphorylation status.

  This differential regulation has implications for therapeutic strategies targeting the angiopoietin-TIE2 axis in diseases characterized by vascular abnormalities.

• What is the relationship between TIE2 Y1102 phosphorylation and different cellular contexts?

  TIE2 Y1102 phosphorylation has context-dependent functions:

  • Quiescent endothelial cells: In cells with established cell-cell contacts, ANGPT1 oligomers recruit TIE2 to these junctions, forming complexes with TIE2 molecules from adjoining cells. Y1102 phosphorylation here leads to PI3K/AKT activation, promoting vascular stability .

  • Migrating endothelial cells: In cells lacking cell-cell adhesions, ANGPT1 recruits TIE2 to contacts with the extracellular matrix. Y1102 phosphorylation in this context contributes to focal adhesion complex formation and activation of PTK2/FAK and MAPK pathways, stimulating sprouting angiogenesis .

  • Spatial localization: Phosphorylated TIE2 is recruited to different cellular compartments depending on context - cell-cell contacts in quiescent vessels versus extracellular matrix contacts in migrating cells, with distinct downstream signaling consequences .

• How can Phospho-TEK (Y1102) antibodies be incorporated into single-cell multi-omics approaches?

  Phospho-TEK (Y1102) antibodies can be integrated into advanced single-cell technologies through DNA-oligo conjugation strategies:

  1. Antibody-oligo conjugation: The antibody can be conjugated with complex 15 nt indices as part of a larger DNA-oligo using methods like TCO-labeling (tetrazine-trans-cyclooctene chemistry) .

  2. Compatibility with platforms:

     • Using TSB tags (10X feature barcodes) for integration with 10X Genomics platforms

     • Using TSA tags (Poly A) for compatibility with poly-A capturing technologies like InCite-seq or NEAT-seq

  3. Multiplexing capacity: This approach allows multiplexing with up to 100 antibodies simultaneously, enabling comprehensive signaling pathway analysis .

  4. Selection criteria: For successful integration, choose antibody clones that work well in Intracellular Flow Cytometry or Immunocytochemistry, as these methods also use fixed, permeabilized cells .

  This approach enables simultaneous profiling of TIE2 phosphorylation status alongside transcriptomics or other protein markers at single-cell resolution.

Methodological Questions

• What are the optimal fixation and sample preparation protocols for preserving TIE2 Y1102 phosphorylation?

  To preserve phosphorylation status for detection with Phospho-TEK (Y1102) antibodies:

  1. Fixation options:

     • For flow cytometry: BD Cytofix fixation buffer or BD Phosflow Fix Buffer I are recommended

     • For IHC: Use formalin fixation followed by paraffin embedding

     • For IF/ICC: 4% paraformaldehyde is typically suitable

  2. Sample processing timeline: Minimize time between sample collection and fixation to prevent phosphatase activity

  3. Phosphatase inhibitors: Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride) in all buffers until fixation is complete

  4. Temperature considerations: Process samples at 4°C when possible before fixation to minimize phosphatase activity

  5. Stimulation conditions: For positive controls, treat samples with angiopoietin-1 (recommended concentration: 600 ng/mL for 5 minutes)

• How should I validate the specificity of Phospho-TEK (Y1102) antibody in my experimental system?

  A comprehensive validation approach includes:

  1. Phosphopeptide competition: Pre-incubate the antibody with the phosphopeptide corresponding to TIE2 Y1102 region before application to samples - this should block specific signal

  2. Non-phosphopeptide control: Pre-incubation with the non-phosphorylated version of the same peptide should not affect antibody binding

  3. Phosphatase treatment: Treat duplicate samples with lambda phosphatase to remove phosphate groups - this should eliminate specific signal

  4. Site-directed mutants: Compare antibody reactivity between wild-type TIE2 and a Y1102F (tyrosine to phenylalanine) mutant after angiopoietin stimulation

  5. Induction verification: Show signal increase after stimulation with angiopoietin-1 (600 ng/mL for 5 minutes is a typical condition)

  These validation steps should be performed within the specific experimental context and application method you intend to use.

• What are the recommended dilutions and detection methods for different applications?

  Application	Recommended Dilution	Detection Method	Notes
  Western Blot	1:500-2000 (or 1 μg/mL)	HRP-conjugated secondary antibody	Use reducing conditions and Immunoblot Buffer Group 1
  IHC-Paraffin	1:100-1:300 (or 5-15 μg/mL)	HRP-DAB detection system	Counterstain with hematoxylin; include no-primary antibody control
  Immunofluorescence	1:50-200	Fluorophore-conjugated secondary antibody	Include DAPI nuclear counterstain
  ELISA	1:40000	Appropriate ELISA detection system	Use validated ELISA detection system
  Flow Cytometry	1×10^6 cells in 100-μL sample	Direct fluorophore conjugate (e.g., Alexa Fluor 488)	BD Cytofix or BD Phosflow Fix Buffer I recommended

  For Western blot, a specific band for phosphorylated TIE2 should be detected at approximately 150 kDa .

• How can I optimize signal-to-noise ratio when working with Phospho-TEK (Y1102) antibodies?

  To improve signal-to-noise ratio:

  1. Blocking optimization: Use 0.5% BSA in PBS as described in several product formulations

  2. Antibody titration: Perform careful titration experiments to determine optimal concentration for your specific sample type

  3. Incubation conditions:

     • For Western blot: Overnight at 4°C with gentle rocking

     • For IHC: 15 μg/mL overnight at 4°C

  4. Washing stringency: Increase number of washes and washing buffer volume to reduce non-specific binding

  5. Secondary antibody selection: Use highly cross-adsorbed secondary antibodies to minimize cross-reactivity

  6. Signal amplification: For low abundance targets, consider using signal amplification methods like tyramide signal amplification while maintaining specificity

  7. Negative controls: Always include isotype controls and/or phosphatase-treated samples to assess background levels

Technical Troubleshooting

• What are common technical issues when using Phospho-TEK (Y1102) antibodies and how can they be resolved?

  Issue	Possible Causes	Recommended Solutions
  No signal	Degraded phosphoepitope	Use phosphatase inhibitors during sample preparation
  	Insufficient stimulation	Verify angiopoietin-1 activity and increase concentration
  	Inefficient transfer (Western blot)	Optimize transfer conditions for high molecular weight proteins (~150 kDa)
  High background	Insufficient blocking	Increase blocking time/concentration or change blocking agent
  	Excessive primary antibody	Titrate antibody to optimal concentration
  	Cross-reactivity	Use more stringent washing or alternative secondary antibody
  Inconsistent results	Variable phosphorylation levels	Standardize stimulation conditions and timing
  	Sample degradation	Minimize time between collection and processing
  Multiple bands (Western blot)	Proteolytic processing	Add protease inhibitors during sample preparation
  	Cross-reactivity	Verify with phosphopeptide competition

• How stable are conjugated Phospho-TEK (Y1102) antibodies and what are the optimal storage conditions?

  Based on information about antibody stability in related applications:

  1. Unconjugated antibodies:

     • Lyophilized: 12 months at -20 to -70°C as supplied

     • Reconstituted: 1 month at 2-8°C or 6 months at -20 to -70°C under sterile conditions

  2. DNA-oligo conjugated antibodies (for Phospho-seq applications):

     • Remain functional after at least one year when stored at 4°C

  3. Fluorophore-conjugated antibodies:

     • Follow manufacturer's guidelines for specific fluorophores

     • Generally stable at 4°C protected from light for several months

  4. Reconstitution recommendations:

     • Reconstitute at 0.2 mg/mL in sterile PBS

     • Aliquot to avoid repeated freeze-thaw cycles

  5. Working solutions:

     • Diluted antibody solutions are typically stable at 4°C for up to one week

     • For longer storage, add carriers like BSA (0.5%) and preservatives

• What controls are essential when using Phospho-TEK (Y1102) antibodies in research applications?

  Essential controls include:

  1. Positive control: Cells/tissues with known TIE2 Y1102 phosphorylation (e.g., angiopoietin-1 stimulated endothelial cells)

  2. Negative controls:

     • Unstimulated samples

     • Lambda phosphatase-treated samples

     • Y1102F mutant (if using transfected cells)

     • Secondary antibody only

  3. Specificity controls:

     • Phosphopeptide competition (should abolish signal)

     • Non-phosphopeptide competition (should not affect signal)

  4. Loading/normalization controls:

     • Total TIE2 antibody on parallel samples

     • Housekeeping proteins for Western blot

     • Tissue/cell type-specific markers for IHC/IF

  5. Technical controls:

     • Isotype control antibody at same concentration

     • Cross-sample standardization (reference sample included in each experiment)

• How can I quantitatively analyze TIE2 Y1102 phosphorylation data across different experimental conditions?

  For quantitative analysis:

  1. Western blot quantification:

     • Normalize phospho-TIE2 signal to total TIE2 protein

     • Use digital image analysis software with linear dynamic range

     • Present data as fold-change relative to control/baseline

  2. Flow cytometry analysis:

     • Calculate median fluorescence intensity (MFI)

     • Determine specific signal by subtracting isotype control MFI

     • Use stimulation index: MFI(stimulated)/MFI(unstimulated)

  3. IHC/IF quantification:

     • Use digital image analysis with standardized acquisition settings

     • Quantify signal intensity in relevant cellular compartments

     • Score percent positive cells and/or staining intensity

  4. Statistical considerations:

     • Perform at least three independent biological replicates

     • Use appropriate statistical tests based on data distribution

     • Account for multiple comparisons when examining various conditions

     • Consider time-course experiments to capture signaling dynamics